PBD-0701
- Generic Name
- PBD-0701
Vir Biotechnology's Dual-Masked T-Cell Engagers Show Promise in Early Cancer Trials
• Vir Biotechnology's VIR-5818 demonstrated tumor shrinkage in 50% of HER2-expressing cancer patients at doses ≥400 µg/kg.
• VIR-5500 showed PSA reductions in 100% of mCRPC patients at initial doses ≥120 µg/kg, with a 58% confirmed PSA50 response.
• Both VIR-5818 and VIR-5500 exhibited promising safety profiles with minimal cytokine release syndrome and manageable adverse events.
• The PRO-XTEN™ masking technology may enable tumor-specific activation and a wider therapeutic index for T-cell engagers.
Vivoryon Shifts Focus to Kidney Disease After Varoglutamstat Fails in Alzheimer's Trial
• Vivoryon's VIVA-MIND Phase IIa trial of varoglutamstat in early Alzheimer's disease failed to meet its primary and secondary endpoints, mirroring previous unsuccessful VIVIAD trial.
• Despite the setback in Alzheimer's, VIVA-MIND data revealed a statistically significant improvement in kidney function, specifically an increase in eGFR compared to placebo.
• Vivoryon will now prioritize the development of varoglutamstat for diabetic kidney disease and potentially other kidney conditions like Fabry disease and Alport syndrome.
• The company's stock prices initially surged following the kidney function findings but remain below levels prior to the negative Alzheimer's results.
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath